Daily Picks

Wall Street has spent the first half of this week revising its story. One bank now thinks Salesforce can ride the AI wave; another sees Adobe’s growth story cracking. Analysts have rediscovered biotech catalysts, a possible Vans turnaround, and a crypto company trying to become a data-center operator.

These calls are useful. They tell us where the debate is moving. But they also show how quickly an analyst can move from “avoid” to “buy,” or turn an optimistic thesis into a tidy target-price revision. The interesting question is not whether a target went up. It is what has changed in the business—and what still needs to go right for the target to make sense.

AI software: Salesforce gets the vote; Adobe gets the warning

Bank of America made one of the week’s sharpest changes, upgrading Salesforce from Underperform to Buy and lifting its target to $285 from $160. The firm’s thesis is that AI adoption may reinforce rather than replace enterprise platforms: large companies still depend on systems that manage their business logic, data, workflows and compliance. BofA’s previous concern was that AI would disintermediate those platforms.

That is a coherent argument, but it remains an argument. “Enterprises already use this software” does not automatically mean AI creates more paid seats, larger contracts or better margins. Even the Yahoo Finance recap flags uncertainty around adoption and says AI-related revenue remains small relative to Salesforce’s overall business.

Adobe got the opposite treatment. Wells Fargo double-downgraded it to Underweight from Equal Weight and cut its target to $225 from $270, citing muted quarterly results and signs of cracks in the growth profile. The next day, HSBC cut Adobe from Buy to Hold and lowered its target to $267 from $310, pointing to reports of a free, open-source clone of parts of Creative Cloud.

The paired calls are more useful than either headline alone. AI is not automatically a tailwind for every software company, nor proof that established vendors are doomed. Salesforce and Adobe are research inputs for investors testing two competing claims: can incumbents turn AI into incremental revenue, and can they defend pricing and customer loyalty against new tools? Look for evidence in actual adoption, retention and monetization—not in how dramatically an analyst moved a target.

Biogen: a bigger catalyst story is still a catalyst story

JPMorgan upgraded Biogen to Overweight from Neutral and raised its target to $300 from $210. The firm cited an “increasingly compelling catalyst path” and an improved long-term growth outlook.

A large target increase can sound like a verdict. It is not. In biotech, the word “catalyst” can cover very different things: clinical results, regulatory decisions, launches or evidence that an existing product can sustain growth. Each has its own timetable and failure modes. The summary of JPMorgan’s move does not enumerate the milestones behind that phrase, so investors should not mistake a bullish label for a complete pipeline analysis.

BIIB is a research lead for anyone prepared to examine the assets, trial evidence, regulatory calendar and commercial assumptions one by one. Ask what new information would invalidate the thesis, not just what could make the stock rise. A price target compresses assumptions into one number; it does not remove the uncertainty underneath.

VF Corp.: two upgrades, one Vans turnaround bet

VF Corp. drew upgrades from two firms on Tuesday. Truist moved to Buy from Hold and raised its target to $20 from $14; Piper Sandler moved to Overweight from Neutral and also set a $20 target, up from $16. Truist’s stated case is that Vans may be poised to inflect as fashion preferences shift and new product launches build momentum. The recap does not provide Piper Sandler’s rationale.

That looks like an encouraging vote for a brand recovery. It is still a recovery bet. Two firms arriving at the same target does not mean they share the same model, confidence or evidence—and one of the published summaries leaves Piper’s reasoning unstated. VFC is worth studying for investors who want exposure to a potential apparel turnaround, but the diligence belongs in product sell-through, inventory discipline, margins and whether new launches can sustain demand beyond a short-lived change in fashion.

The skeptical read is straightforward: an upgrade can mark the point when expectations become less bleak, not the point when the turnaround is already working. Investors should separate “less bad than feared” from durable growth.

Galaxy Digital: a crypto call with a data-center kicker

Citi upgraded Galaxy Digital to Buy from Neutral and raised its target to $28 from $26. Its case combines a stronger backdrop for digital assets and greater regulatory clarity with Galaxy’s effort to build an AI data-center business. Citi cited better-than-expected economics at Helios I and said a possible Helios II tenant announcement within six months could improve visibility; that announcement remains a possibility, not a signed outcome.

This is not simply a bet on crypto prices. It is also a bet that a company associated with digital assets can deliver on a capital-intensive infrastructure strategy. That creates two sets of questions: how sensitive is the core business to crypto conditions, and can the data-center assets produce the economics Citi expects? GLXY is a research idea for investors willing to underwrite both sides of that story—not a shortcut around the risks.

The bottom line

This week’s calls span AI software, biotech, apparel and crypto infrastructure. The common thread is not that Wall Street has found four sure things. It is that analysts are adjusting their assumptions—and sometimes making very large changes to the target attached to those assumptions.

Use the calls as prompts, not instructions. Read the thesis, check what evidence would confirm or break it, and decide whether the risk fits your own process. A new rating can start the research. It cannot finish it.

— The Daily Wall Street Alerts Team

This newsletter is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making any investment decisions.